ClinicalTrials.gg
CompletedNCT07934966bronchial anglUpdated Nov 13, 2026

Pulmonary Ligament Division vs Preservation in Upper Lobectomy

An interventional study of Upper lobectomy with pulmonary ligament division and Pulmonary ligament preservation post lobectomy in Lobectomy, Lung Cancer Non-Small Cell Cancer (NSCLC) and Lung Volume, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Feb 2024, registered Oct 2026).
Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 29 studies in Carcinoma, Non-Small-Cell Lung with a site in Egypt — none open to participants now, 1 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Egypt.

Enrollment
19th of 19
40 · median 263
Started
2024
the only one that year
No phase
Only one
of the 29
Registered
29th of 29
by date
Lead sponsor
5 of 29
Ain Shams University

Among the 29 studies in Carcinoma, Non-Small-Cell Lung with a site in Egypt, this one is the 19th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2024, is the only one with no phase, and was the 29th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 29 studies in Carcinoma, Non-Small-Cell Lung with a site in Egypt is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Carcinoma, Non-Small-Cell Lung with a site in Egypt as a file.
02

Study summary

This study looks at two different surgical techniques used during lung surgery (upper lobectomy). Surgeons may either divide or preserve a thin tissue band called the pulmonary ligament. The investigators want to understand how this choice affects recovery, including changes in lung size, airway shape, and symptoms such as cough. Forty patients took part, with half receiving ligament division and the other half with ligament preservation post upper lobectomy. Lung volume and airway changes were measured using CT scans, and cough scores were recorded after surgery. The study also noted one patient in the division group who developed a space problem (pneumothorax) two weeks after surgery. The goal is to learn which approach may help patients recover more comfortably and reduce postoperative symptoms.

03

Conditions studied

  • Lobectomy
  • Lung Cancer Non-Small Cell Cancer (NSCLC)
  • Lung Volume

Keywords

  • Pulmonary ligament division
  • Pulmonary ligament preservation
  • Bronchial geometry
  • Curvature index (CI)
  • Postoperative cough
  • Randomized controlled trial
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age group 18-70 years old
  2. Any mass in the upper lobe presented for upper lobectomy
  3. Patients presented for bilobectomy for whatever cause
  4. Preoperative score of 0-1, preoperative ASA scores 1-2

Exclusion criteria

Exclusion Criteria:

  1. Patients with age extremities \<17 and >70 years old
  2. Severe thoracic adhesions found during surgery
  3. Inadequate CT images (as patients with extensive breathing motion artifacts that hinder proper measurements of the bronchial angles and lung volumetry)
  4. Found that a larger-scale operation is required due to multiple lesions
  5. Lost to follow-up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    pulmonary ligament dissection arm

    inferior pulmonary ligament dissection post lobectomy

    Procedure: Upper lobectomy with pulmonary ligament division

  • Active comparator
    pulmonary ligament preservation arm

    the inferior pulmonary ligament will be preserved after upper lobectomy

    Procedure: Pulmonary ligament preservation post lobectomy

Interventions

  • ProcedureUpper lobectomy with pulmonary ligament division

    Division Group (Experimental Arm): In this group, the inferior pulmonary ligament is surgically divided during upper lobectomy. Division removes the ligament's natural support, allowing the residual lung to expand and shift more freely within the pleural cavity. This maneuver is hypothesized to influence postoperative bronchial geometry, lung-volume reduction, and cough severity. Unlike standard lobectomy protocols where ligament management is not isolated, this intervention specifically evaluates the impact of ligament division as the primary variable of interest.

  • ProcedurePulmonary ligament preservation post lobectomy

    Preservation Group (Comparator Arm): In this group, the inferior pulmonary ligament is left intact during upper lobectomy. Preserving the ligament maintains the natural anatomical support of the residual lung and may reduce postoperative displacement or distortion of the bronchial tree. Unlike other thoracic surgical interventions that routinely divide the ligament, this approach specifically evaluates whether preservation minimizes postoperative lung-volume reduction, cough severity, and space-related complications. The preservation strategy therefore serves as a comparator to ligament division, isolating the effect of ligament management on postoperative anatomical and clinical outcomes.

06

What researchers measure

Primary outcomes

  1. Bronchial Angle

    The change in bronchial angulation pre- and post-operatively

    Time frame: From enrollment post operative to the end of treatment at 2 weeks

  2. Lung Volume

    The difference in lung volume pre- and post-operatively using CT 3D reconstructive imaging

    Time frame: From enrollment post operative to the end of treatment at 2 weeks

Secondary outcomes

  1. Irretractable post lobectomy cough

    Development of post-operative symptomatic cough (unresponsive to expectorants or mucolytics) / measured using the COAT sheet for cough assessment

    Time frame: post intervention by 2-3 weeks

  2. length of hospital stay

    The length of hospital stay per patient in days post operative

    Time frame: From completion of the intervention until the first chest X-ray showing normal findings and no air leak, assessed up to 21 days after the intervention.

07

Study locations

1 site
  • Ain Shams University Hospitals - Faculty of medicine
    Cairo, Cairo (C) 11771, Egypt
08

References and documents

Publications

  • Lv H, Zhou R, Zhan X, Di D, Qian Y, Zhang X. The choice of dissection or preservation of the inferior pulmonary ligament after an upper lobectomy: a systematic review and meta-analysis. World J Surg Oncol. 2020 Jan 4;18(1):5. doi: 10.1186/s12957-019-1777-3. PubMed 31901232 ↗
  • Seok Y, Cho S, Lee JY, Yang HC, Kim K, Jheon S. The effect of postoperative change in bronchial angle on postoperative pulmonary function after upper lobectomy in lung cancer patients. Interact Cardiovasc Thorac Surg. 2014 Feb;18(2):183-8. doi: 10.1093/icvts/ivt463. Epub 2013 Nov 14. PubMed 24243734 ↗
  • Ueda K, Tanaka T, Hayashi M, Tanaka N, Li TS, Hamano K. Clinical ramifications of bronchial kink after upper lobectomy. Ann Thorac Surg. 2012 Jan;93(1):259-65. doi: 10.1016/j.athoracsur.2011.08.065. Epub 2011 Nov 17. PubMed 22098920 ↗
  • Matsuoka H, Nakamura H, Nishio W, Sakamoto T, Harada H, Tsubota N. Division of the pulmonary ligament after upper lobectomy is less effective for the obliteration of dead space than leaving it intact. Surg Today. 2004;34(6):498-500. doi: 10.1007/s00595-004-2752-2. PubMed 15170544 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — population demographic data and clinical characteristics of the studied patients

Supporting information: Study protocol, Informed consent form

Time frame: May 1st 2026 till end of December 2026

Access criteria: Authors, editors and Faculty registered colleagues

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Feb 2026, 24 months.

Of 344 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 98. This study's 24 months is below that.

Counting every sponsor, half of 360 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2026
First posted
Nov 13, 2026
StartActual
Feb 1, 2024
Primary completionActual
Feb 28, 2026
CompletionActual
Jun 1, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07934966
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Feb 1, 2024
Primary completion
Feb 28, 2026
Completion
Jun 1, 2026
Last update
Nov 13, 2026

Study contacts

Hany Hassan El-sayed, Professor
study director · Ain Shams University Hospitals - Faculty of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion